Canada bans Indian API maker; Congress looks at antibiotics development; Former Pfizer site proves tricky for town;

@FiercePharma: Eylea gets yet another approval, this one in Japan. More | Follow @FiercePharma

@EricPFierce: Potentially bad news for Amphastar and its $155.7M deal if Sanofi makes insulin for Mannkind. Article | Follow @EricPFierce

@CarlyHFierce: Inversion pushback won't scare Horizon Pharma out of Ireland move. Story | Follow @CarlyHFierce

> Canada has ordered Indian API maker IPCA to stop exporting there after the FDA reviewed information that led the agency to ban its products. Story

> The U.S. Congress is considering more legislation that could lead to the development of more drugs to overcome antibiotic resistance. Story

> Lake Forest, IL-based Akorn ($AKRX) last year had about $320 million in sales but expects to use acquisitions to become a $1 billion revenue generator. Report

Medical Device News

@FierceMedDev: Zimmer partners with MiMedx to sell bioimplants to promote healing. Article | Follow @FierceMedDev

@MichaelGFierce: Vaxxas' nanopatch garners WHO support in search of #polio vax application. Story | Follow @MichaelGFierce

@VarunSaxena2: Court ruling against FDA should enable more combination products to be classified as devices. Article | Follow @VarunSaxena2

@EmilyWFierce: British startup launches crowdfunding effort for 3-D printed orthotic devices. More | Follow @EmilyWFierce

> University of Louisville working on 'bioficial heart' using 3-D printing. Story

> Physicians defend power morcellator devices amid industry fallout. Article

Biotech News

@FierceBiotech: FierceBiotech's 2014 Fierce 15. Congrats to those who made the list! | Follow @FierceBiotech

@JohnCFierce: Always fun to watch the web traffic explode when we blast the Fierce 15. | Follow @JohnCFierce

@DamianFierce: Merck KGaA gets around to that big deal it's been talking up: $SIAL for $17B. More | Follow @DamianFierce

> Tekmira hammers out a way to get its Ebola drug to patients. News

> Amgen pushes for early FDA OK of leukemia drug blinatumomab. Story

> Regeneron touts its allergy drug as a blockbuster in waiting. Article

CRO News

> Packaging outfit PCI buys trial supplier Biotec. News

> Survey says: Big CROs are only getting bigger. Report

> CRO FlowMetric gets into diagnostics with new spinout. Story

> TransCelerate dishes on risk-based monitoring. Item

> Covance borrows Fresenius' data to improve kidney treatments. Article

Biotech IT News

> Vivametrica makes pitch for mHealth data aggregation and analysis market. Report

> Stanford and Duke to trial Apple's HealthKit for remote data collection. More

> Merck survey finds patients willing to share NGS data with pharma companies. Story

> BBK bags $3M to expand its eClinical suite. Item

> AstraZeneca opens Indian IT center as 13-year outsourcing experiment nears end. Article

Animal Health News

> Work on the National Bio and Agro-Defense Facility continues. More

> EU gives nod to Merck's poultry vaccine to fight infectious bronchitis. Report

> Phibro reports strong sales in animal growth and nutrition sectors. Article

> Will Zoetis stand alone when Big Pharma's music stops? More

> Packaging outfit PCI buys trial supplier Biotec. Story

And Finally... A former Pfizer ($PFE) site in Morris Plains, NJ, is in legal limbo. Story

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.